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Background: Gastroparesis is common in surgical patients and frequently leads to the need for enteral tube feeding.
Nasoenteral feeding tubes are usually placed endoscopically by gastroenterologists, but this procedure is relatively
cumbersome for patients and labor-intensive for hospital staff. Electromagnetic (EM) guided bedside placement of
nasoenteral feeding tubes by nurses may reduce patient discomfort, workload and costs, but randomized studies are
lacking, especially in surgical patients. We hypothesize that EM guided bedside placement of nasoenteral feeding tubes
is at least as effective as endoscopic placement in surgical patients, at lower costs.
Methods/Design: The CORE trial is an investigator-initiated, parallel-group, pragmatic, multicenter randomized
controlled non-inferiority trial. A total of 154 patients admitted to gastrointestinal surgical wards in five hospitals,
requiring nasoenteral feeding, will be randomly allocated to undergo EM guided or endoscopic nasoenteral feeding
tube placement. Primary outcome is reinsertion of the feeding tube, defined as the insertion of an endoscope or tube
in the nose/mouth and esophagus for (re)placement of the feeding tube (e.g. after failed initial placement or
dislodgement or blockage of the tube). Secondary outcomes include patient-reported outcomes, costs and tube
(placement) related complications.
Discussion: The CORE trial is designed to generate evidence on the effectiveness of EM guided placement of
nasoenteral feeding tubes in surgical patients and the impact on costs as compared to endoscopic placement.
The trial potentially offers a strong argument for wider implementation of this technique as method of choice for
placement of nasoenteral feeding tubes.
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Gastroparesis, or delayed gastric emptying, occurs in ap-
proximately 2% of surgical patients [1,2]. It is caused by
the disease itself, an operation, postoperative complica-
tions such as intra-abdominal infection, or concomitant
underlying diseases such as diabetes. Patients suffering
from gastroparesis do not tolerate a normal diet and
may eventually become malnourished, which negatively
affects clinical outcomes [3-5]. Therefore, in patients
who are not able to achieve at least 50% of their daily re-
quired caloric intake for several consecutive days, it is
common practice to place a nasoenteral feeding tube to
deliver enteral nutrition. Parenteral nutrition is only
used when enteral nutrition is contraindicated, not feas-
ible or not sufficient in delivering nutrient needs, as par-
enteral nutrition has shown to be associated with an
increase in infectious complications and higher costs [6].
Nasoenteral feeding tube placement can be challen-
ging, especially in patients with gastroparesis. Blind
placement is usually unsuccessful and may lead to com-
plications such as pneumothorax and pneumonia due to
inadvertent placement in the bronchus in over 2% of
placement attempts [7].
Therefore, nasoenteral feeding tubes are usually placed
endoscopically, regularly followed by abdominal radiog-
raphy to confirm a correct position of the tube. Endo-
scopic feeding tube placement requires fasting and
patient transportation between the clinical ward, endos-
copy and radiology departments. The procedure is also
relatively expensive as it has to be performed by a
gastroenterologist and one or two endoscopy nurses.
Hence, both patients and hospital staff perceive endo-
scopic tube placement as uncomfortable and cumbersome.
Furthermore, patients may need several repeated proce-
dures during hospital admission. We noticed a 34% dis-
lodgement rate of nasoenteral feeding tubes within the
first week after placement [8]. Some 50% of these dis-
lodged tubes require replacement, which not only leads to
additional discomfort for the patient and temporary
decrease in caloric intake, but also to an increased work-
load for nursing and medical staff, and additional costs.
Electromagnetic (EM) guided placement of nasoent-
eral feeding tubes is suggested to be less discomforting
to the patient and seems cost-saving compared with en-
doscopy, as it can be performed on the clinical ward at
the patient’s bedside by a specialized nurse. Confirm-
ation of the tube’s position on an abdominal radiograph
is unnecessary and repositioning of a tube that has dis-
lodged into the stomach can be done with the stylet
without the need for a fully repeated procedure [9-12].
Implementation of this technique requires training of
nurses (e.g. a full-day training session, ideally followed
by a number of supervised placement procedures) and
purchasing the equipment ($ 7925) [10,13].A recent systematic review by our group showed that
EM guided tube placement in adult patients is not infer-
ior to endoscopic placement regarding efficacy and
safety in patients with normal upper gastrointestinal
(GI) anatomy [14]. Success rates were similar and only
minor complications such as epistaxis and dislodgement
or blockage of the tube were reported. However, the
available evidence is of moderate quality and lacks data
on patient-reported outcomes and costs. Moreover, stud-
ies in surgical patients, especially those with an altered
upper GI anatomy after surgery, are scarce. In our previ-
ous retrospective cohort study, EM guided placement
was successful in 58% of patients with an altered upper
GI anatomy, which seems low, but may be acceptable
given the potential benefits for the patient [15]. A well-
designed pragmatic, multicenter, randomized controlled
trial is therefore needed to assess the true effectiveness
and benefits of EM guided nasoenteral feeding tube
placement in the surgical population.
The aim of the CORE trial is to determine the effect-
iveness of EM guided bedside placement as compared to
endoscopic placement of a nasoenteral feeding tube in
surgical patients requiring nasoenteral feeding.
Methods
Design
The CORE trial is an investigator-initiated, parallel-
group, pragmatic, multicenter, randomized controlled
non-inferiority trial. Patients will be randomly allocated
to undergo EM guided or endoscopic nasoenteral feed-
ing tube placement.
Study population
All adult patients admitted to the gastrointestinal surgi-
cal wards in one of the five participating centers with an
indication for post-pyloric enteral nutrition will be
assessed for eligibility, regardless of the reason for ad-
mission (e.g. surgical procedures or conditions not re-
quiring surgery).
Inclusion criteria
Inclusion criteria are: admission to a gastrointestinal sur-
gical ward; need for post-pyloric enteral nutrition via
nasoenteral feeding tube as indicated by the treating
physician and/or consulting dietitian (e.g. because of se-
vere gastroparesis/gastric stasis not responding to proki-
netics, intolerance of oral feeding due to gastroduodenal
inflammation, postprandial pain or passage disorder due
to swelling or outside pressure onto the duodenum or
proximal enteric fistulae); and written informed consent.
Exclusion criteria
Exclusion criteria are: age < 18 years; presence of a contra-
indication for enteral feeding; presence of a
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of esophageal varices, upper GI stenosis or obstruction, re-
cent (<30 days) esophagectomy, or the presence of an im-
planted medical device that may be affected by the
electromagnetic field of the EM guided system or vice
versa (except for pacemakers and defibrillators) and neces-
sity for tube placement during weekends or holidays.
Randomization
Eligible patients will be recruited on the clinical ward by
the principal investigators or a designated substitute.
After obtaining informed consent, patients will be ran-
domized centrally by the study coordinator using an on-
line randomization module (Clinical Research Unit,
Academic Medical Center, Amsterdam, the Netherlands)
in a 1:1 ratio between EM guided and endoscopic tube
placement (Figure 1).
Randomization will be stratified by center to balance
differences in general treatment regimens between hos-
pitals and according to the presence of an altered upper
GI (esophageal, gastric or duodenal) anatomy after pre-
vious surgery. Randomization is balanced for the pres-
ence of an altered upper GI anatomy because an altered
anatomy might hamper feeding tube placement and de-
crease success rates. Permuted-block allocation is used
to provide treatment allocation in equal proportions.Surgical patients in need of nas
feeding assessed for eliglib















77 allocated to electromagnetic 
guided tube placement 
77
4 lost to follow up
73 analyzed
Figure 1 Flow chart of participants in the CORE trial according to COThe block size will be subject to random variation and
concealed to all investigators involved in the study.
Blinding of patients and caregivers was considered
practically unfeasible given the obvious differences be-
tween the two methods of tube placement (e.g. bedside
placement or placement in the endoscopy department).
Moreover, the primary outcome (reinsertion of an endo-
scope of tube) is sufficiently objective to minimize any
potential risk of measurement bias. Feeding tubes are
reinserted when oral intake is less than 50% of the pa-
tient’s daily required caloric intake. This decision will be
made by the treating physician, whenever possible after
consulting a dietitian.
Group A: Electromagnetic guided nasoenteral feeding
tube placement
The feeding tube (Corflo® nasojejunal feeding tube, Corpak
Medsystems, Wheeling, Ill, US) is placed by a trained nurse
at the patient’s bedside on the clinical ward, with the
patient in a supine position. If a nasogastric decompression
tube is in place, it is advised, but not mandatory, to empty
the stomach and remove the nasogastric tube before pro-
ceeding. Preprocedural fasting is not required. By using an
electromagnetic transmitting stylet, the nurse can follow
the path of the tip of the feeding tube on a monitor screen
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feeding tube transmits its signal to a receiver unit placed at
the patient’s epigastric region. Both the stylet and the re-
ceiver unit are attached by a cable to the monitor unit,
which provides a graphic display of the feeding tube tip lo-
cation and the followed track. In the anterior view, the tube
can be followed on its way through the esophagus, stom-
ach, duodenum, and jejunum. In the depth cross-section,
the passage of the tube from the pylorus into the duodenal
bulb and the second part of the duodenum can be seen.
The tube is advanced to a post-pyloric position, preferably
near or beyond the duodenojejunal flexure. Adequate posi-
tioning is assessed by the path of the tube on the screen.
Subsequently, the transmitting stylet is removed from the
feeding tube. Finally, the tube is secured to the nostrils
with tape. Abdominal radiographs are not used, as the
Cortrak® Enteral Access System was shown to correlate
with abdominal radiography in 99.5% of cases and is
cleared by the Food and Drug Administration (FDA) for
feeding tube placement confirmation [9,11]. The stylet is
kept at the patient’s bedside in case repositioning of the
nasoenteral tube is required. The procedure is aban-
doned if the tip of the tube has not passed the pylorus
after 30 minutes. In case of failure of EM guided place-
ment, patients allocated to EM guided bedside place-
ment will undergo endoscopic placement. According to
the intention-to-treat principles these patients will be
analyzed in the EM guided group.Figure 2 The Cortrak® Enteral Access System (electromagnetic
transmitting stylet, receiver unit and enteral feeding tube).
The tip of the tube is displayed on the monitor as a red dot and a
yellow line reflects the path of the tube. Image reproduced with
permission of CORPAK MedSystems.Group B: Endoscopic nasoenteral feeding tube placement
Endoscopy is performed by trained gastroenterologists
(or supervised gastroenterologists in training) assisted by
one or two endoscopy nurses in the endoscopy depart-
ment. Patients fast from midnight but clear fluids are
allowed up to 3 hours before the procedure. Conscious
sedation is used if indicated (e.g. requested by the pa-
tient). A nasal or oral endoscope is introduced into the
duodenum or jejunum. According to the gastroenterolo-
gist’s preference, the feeding tube is either pulled along
with the endoscope, advanced through the endoscope or
advanced over a guide wire and placed as far as possible
in the duodenum or jejunum. Finally, the tube is secured
to the nostrils with tape. Within 3 hours after tube
placement, an abdominal radiograph is performed and
reviewed by an independent radiologist who is not in-
volved in the study. In case of incorrect feeding tube
placement, repeat endoscopic tube placement is per-
formed. In case of second placement failure, the study is
terminated for that patient and an alternative feeding
strategy (but not EM guided placement) is used accord-
ing to the preference of the treating physician.
General treatment regimen
After confirmation of the correct position of the feeding
tube, enteral nutrition is initiated and increased to the
required amount as advised by the treating physicians,
whenever possible after consulting a dietitian. The
dietitian can advise on a schedule for the resumption of
oral feeding during enteral nutrition. When enteral nu-
trition is no longer indicated (i.e. oral intake exceeding
50% of the patient’s daily required caloric intake with an
upward trend), it is ceased and the feeding tube is re-
moved. These decisions are not influenced by the
method by which the enteral feeding tube was placed.
In patients with symptoms of dislodgement (e.g. nau-
sea, vomiting or reflux of tube feeding via the nasogas-
tric tube), dislodgement of the nasoenteral feeding tube
will be confirmed on abdominal radiograph or Cortrak®
monitor (by reinsertion of the stylet). In patients with
blockage of the tube (i.e. inability to pass tube feeding
through the tube), an attempt will be made to resolve
the clogging by flushing of the tube with water or acetyl-
cysteine. In case of confirmed dislodgement or irrevers-
ible blockage of the tube, replacement (or repositioning
if possible) will be performed with the allocated tech-
nique, except after conversion from EM guidance to en-
doscopy after failed initial EM guided placement.
Prokinetic agents (e.g. metoclopramide or erythromycin)
can be used according to the preference of the treating
physician.
Patients are discharged when considered appropriate
by the treating team. In select cases, patients can be dis-
charged with the feeding tube in situ to continue enteral
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care for enteral nutrition is taken over by (nursing)
homecare. Any problems with the tube are taken care of
in the outpatient clinic for as far as possible.
Primary outcome
The primary outcome is the need for reinsertion of the
feeding tube, defined as the insertion of an endoscope or
tube in the nose/mouth and esophagus for (re)placement
of the feeding tube. This outcome reflects the feasibility
of the technique itself as well as the need for repeated
procedures due to tube-related complications. Tubes will
be reinserted when there is an ongoing indication for en-
teral feeding (as advised by the consulting dietitian) after
initial unsuccessful placement, dislodgement or blockage
of the tube. Endoscopic placement after failed initial EM
guided attempt (crossover) is also considered a reinser-
tion. Repositioning guided by the EM transmitting stylet
is not considered a reinsertion as long as the tube has
not left the stomach/esophagus.
Secondary outcomes
EM guided placement of a nasoenteral feeding tube is
hypothesized to be less discomforting to the patient
compared to endoscopic placement, at lower costs. Sec-
ondary outcomes therefore include: patient-reported
outcomes (e.g. pain, discomfort, and total burden) and
costs of both tube placement procedures. The costs will in-
clude the direct and indirect medical costs of initial tube
placement (including personnel, materials, sedation, equip-
ment and transport), tube related complications, diagnostic
investigations, and feeding related interventions.
Other secondary outcomes are: the success rate of tube
placement; duration of the tube placement procedure;
time between physician order and tube placement and
start of feeding; time to reach the feeding goal; all feeding
related interventions (including EM guided repositioning
without reinsertion of the tube) with corresponding indi-
cation; duration of tube stay; tube (placement) related
complications (such as dislodgement, blockage, epistaxis,Table 1 Definitions of outcomes
Outcome Definition
Reinsertion The insertion of an endoscope or tube in the nose/m
Repositioning Reinsertion of the EM transmitting stylet when the t
Dislodgement Any displacement of the feeding tube making conti
stomach in the presence of gastroparesis) or imposs
on the Cortrak® monitor or abdominal radiograph.
Blockage The inability to pass tube feeding through the tube
Successful tube
placement
The tip of the feeding tube positioned beyond D2 [p
the efferent jejunal limb (in the presence of a gastro
radiograph (depending on the placement method)
the stomach.
Duration of tube stay The number of days that the feeding tube was in itsaspiration); use of parenteral nutrition; length of hospital
stay; and in-hospital mortality (see Table 1 for definitions).
Data collection and follow-up
Clinical data with regard to baseline characteristics and
outcomes will be collected during hospital admission
using written standardized case report forms (CRFs)
(Figure 3). The CRFs will be completed by the local
treating physicians or the study coordinator. The CRFs
will be checked with source data by the primary and/or
secondary study coordinator. The utilization of health-
care in terms of direct medical costs of initial tube place-
ment, sedation, tube-related complications, diagnostic
investigations, and feeding related interventions will be
registered as part of the data collection for the trial.
Patients will be asked to complete a short questionnaire
after each tube (re)placement procedure. The question-
naire will consist of a visual analogue scale (VAS) scoring
sheet, for the dimensions discomfort, pain, social embar-
rassment, anxiety, and total burden (comparable to the
study by Deutekom et al. [16]). In addition, patients will
also be asked what their advice would be to a friend or
colleague in the same situation. Patients randomized to
EM guided tube placement with past experiences with
endoscopic tube placement and vice versa will additionally
be asked for their preference for one or the other tube
placement method.
Patients are followed for as long as they are hospitalized
and during any outpatient clinic or day-care visit related
to the feeding tube (see Additional file 1 for the time
schedule of enrolment, interventions, and assessments).
Safety
All physicians involved in the study will be instructed to
contact the coordinating investigator in case of mortality
or tube (placement) related unexpected adverse events
leading to prolonged hospitalization. All severe adverse
events that may be related to the feeding tube or place-
ment procedure and all cases of mortality will be re-
ported to the Central Committee on Research involvingouth and esophagus for (re) placement of the feeding tube.
ube has not left the stomach/esophagus.
nuation of tube feeding unsafe (e.g. because it is delivered into the
ible (e.g. when the tube has been removed from the patient), confirmed
whilst it is still in the correct position.
referably near the ligament of Treitz (i.e. duodenojejunal flexure)] or in
- or duodenoenterostomy) on the Cortrak® monitor or abdominal
followed by successful enteral feeding, without signs of feeding entering
correct position.
Figure 3 CORE trial flow chart of eligibility and group allocation.
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gebonden Onderzoek) and the Institutional Review
Board using an online module [17]. Due to the perceived
negligible risk associated with participation in this study,
monitoring by a Data Safety Monitoring Board is not re-
quired according to Dutch legislation.
Ethics
The study will be conducted according to the principles
of the Declaration of Helsinki (59th version, October
2008) and in accordance with the Dutch Medical
Research Involving Human Subjects Act (WMO). The
independent ethics review board of the Academic Med-
ical Center (Amsterdam, the Netherlands) has approved
the study protocol. Secondary approval was obtained
from the boards of the Canisius Wilhelmina Hospital,Gelre Hospital, Hospital Gelderse Vallei, and University
Medical Center Utrecht according to the Dutch CCMO
External Review Directive 2012 (RET 2012). Written in-
formed consent will be obtained from all participating
patients prior to randomization. The trial is registered in
the Dutch Trial Register (http://www.trialregister.nl/trial-
reg/index.asp) with identification number NTR4420.
Statistical aspects
Sample size calculation
The CORE trial is designed as a non-inferiority trial, hy-
pothesizing that the need for reinsertion of a nasoenteral
feeding tube after EM guided placement is at most 10%
worse as compared to endoscopic placement.
Sample size is calculated based on data from previous
studies and experiences from our pilot study.
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tion of an endoscope or tube. We estimate a success rate
of 78% in the EM guided group versus 70% in the endo-
scopic group. When the non-inferiority limit is set at
10%, significance level at 0.05 and power at 80%, the
sample size required per study arm is 73 [18]. Taking
into account a 5% loss to follow-up rate (based on previ-
ous studies), a total of 154 patients will have to be ran-
domized in this study.
Descriptive statistics
For dichotomous data, frequencies will be presented.
Continuous data will be presented as means and stand-
ard deviations or medians and interquartile ranges, de-
pending on their distribution. Baseline characteristics
(all prior to randomization) include: age, sex, body mass
index, American Society of Anesthesiologists (ASA)
physical status, indication for hospital admission, type of
surgery (if applicable), indication for enteral nutrition,
cause of gastroparesis (if applicable), interval between
surgery and primary tube placement, use of prokinetic
agents and presence of an altered upper GI anatomy
after previous surgery.
Analyses
All analyses will be according to the intention-to-treat
principles, meaning that all randomized patients are in-
cluded in their initially assigned study arm, regardless of
adherence to study protocol. The primary and secondary
outcomes will be compared between the treatment
groups. Results are presented as risk ratios with corre-
sponding 95% confidence intervals. Except for the
primary analysis of non-inferiority, a difference with a
two-tailed P < 0.05 is considered statistically significant.
In the event of imbalance between the two study arms a
multivariable logistic regression will be used to correct
for possible confounders. Additional as-treated and per-
protocol analyses will be performed for the primary
endpoint and the success rate of both tube placement
methods.
A predefined subgroup analysis will be performed in
patients with and without an altered upper GI anatomy
after previous surgery. We will use logistic regression
models to perform a formal test for interaction to assess
whether outcomes differed significantly between these
subgroups.
Interim analysis to evaluate serious adverse events and
potentially prematurely terminate the study will not be
performed, because of the perceived negligible risk asso-
ciated with participation in this study.
Dissemination policy
The trial’s results will be submitted to a peer-reviewed
journal regardless of the outcome. Co-authorship will bebased on the international guidelines with a maximum
of three co-authorships per participating center. Partici-
pating clinicians that do not fulfill these criteria will be
listed as ‘collaborator’ and the journal will be asked to
present the names of all collaborators to be listed in
PubMed. The order of authors will be based primarily
on scientific input and secondarily on the number of
randomized patients.
Discussion
The CORE trial is initiated by gastrointestinal surgeons
and gastroenterologists based on the potential benefits
of EM guided tube placement (e.g. reduced patient dis-
comfort and costs). The study is designed as a multicen-
ter, randomized controlled non-inferiority trial to answer
the question whether EM guided nasoenteral feeding
tube placement is at least as effective as endoscopic
placement in surgical patients. Superiority would, of
course, be preferred, but such a trial would be practically
impossible given the required sample size of nearly a
thousand patients. Moreover, superiority regarding ef-
fectiveness is not required, since EM guided nasoenteral
tube placement may still be recommended if its effect-
iveness is similar, or at least not worse than the non-
inferiority limit, to endoscopic tube placement, because
of the intrinsic advantages of this technique [19].
In contrast to previous studies on EM guided nasoent-
eral feeding tube placement, the CORE trial is an
investigator-initiated randomized controlled multicenter
trial comparing EM guided placement to the current
conventional tube placement method (endoscopy).
Moreover, it does not only focus on successful tube
placement, but also on patient-reported outcomes and
costs. When looking at effectiveness, the success rate of
initial tube placement would have been the most obvious
primary outcome. However, since passage of the tube
through the naso- and oropharynx is considered to be
the most burdensome part of tube placement, a reduc-
tion in reinsertions of the tube seems much more rele-
vant to the patient. In addition, the success of tube
placement is included in this outcome because reinser-
tion is required after failure. Furthermore, EM guided
tube placement might lead to a slight reduction in
necessary reinsertions, since tubes dislodged into the
stomach can be repositioned without removal of the
tube (as is the case with endoscopic replacement).
The study population consists of patients admitted to
gastrointestinal surgical wards who are in need of
nasoenteral feeding whereas previous randomized con-
trolled trials (and the majority of cohort studies) have
only been performed in critically ill patients. This popu-
lation is chosen because the incidence of gastroparesis is
relatively high in these patients, since their GI system is
frequently disordered by an operation, postoperative
Gerritsen et al. Trials  (2015) 16:119 Page 8 of 9complications or the underlying or concomitant disease.
Gastroparesis is especially a problem in patients after ab-
dominal surgery and many feeding strategies have been
investigated [20-22]. The high incidence of gastroparesis
may not only lead to a frequent need for nasoenteral
feeding, but it also hampers post-pyloric tube placement
due to gastric stasis. Moreover, in a substantial subset of
surgical patients the upper GI anatomy is altered due to
surgery, which may complicate tube placement as, con-
sequently, also the route of the feeding tube has chan-
ged. When a nasoenteral feeding tube placement
method would prove to be successful in the surgical
population, the results can probably be extrapolated eas-
ily to the overall hospital population requiring nasoent-
eral feeding.
In conclusion, the CORE trial is a randomized con-
trolled multicenter trial, which will generate evidence on
the effectiveness of EM guided placement of nasoenteral
feeding tubes in surgical patients and its related costs as
compared to endoscopic placement, and can potentially
offer a strong argument to further implement this tech-
nique as method of choice for placement of nasoenteral
feeding tubes.
Trial status
The first patient was randomized on the 13th of March
2014. As of February 23rd 2015, 133 of 154 patients
(86%) have been randomized and inclusion is progres-
sing according to schedule.
Additional file
Additional file 1: Time schedule of enrolment, interventions, and
assessments of participants in the CORE trial.
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